Clinical trial
Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.
NCT00148551 · Canadian Retinal Trials Group, Other · Unknown status
Key facts
| NCT number | NCT00148551 |
|---|---|
| Title | Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD. |
| Official title | Triamcinolone Acetonide as an Adjunctive Treatment to Verteporfin Therapy in Neovascular Age-Related Macular Degeneration: Randomized Placebo-Controlled Clinical Trial. |
| Lead sponsor | Canadian Retinal Trials Group, Other |
| Collaborators | University of British Columbia QLT Inc. Industry Vancouver Hospital |
| Status | Unknown status |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Age-Related Macular Degeneration |
| Intervention type | Drug |
| Interventions | Triamcinolone Acetonide |
| Enrollment | 120 |
| Start date | Jan 1, 2004 |
| Completion | Mar 1, 2008 |
| First posted | Sep 8, 2005 |
| Last update posted | Jul 30, 2007 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: